Understanding the Science of Vaccine Development:
A Virtual Conversation with Dr. Robert Seder, National Institutes of Health
- How did the NIH work with Moderna to develop their vaccine?
- If I am fully vaccinated, when do I need a booster shot? And will booster shots be ready in time?
- Does it matter what booster shot I get?
- Will the vaccines protect us against the new variants?
Science Writers in New York is proud to present Dr. Robert Seder, chief, Cellular Immunology Section, National Institutes of Health. Dr. Seder will talk to SWINY co-chair David Levine (@dlloydlevine) about the inner workings of COVID-19 vaccine mechanisms and their development, how effective and how long the antibodies they produce will be and whether they will protect us as new variants emerge. He will also discuss innate immunity, adjuvants and personalized cancer vaccine design as well as malaria monoclonal antibodies.
Dr. Seder was involved in the research that led to the approval of Moderna’s candidate mRNA-1273 vaccine, which was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc. He was one of the authors of a study published July 28, 2020 in the New England Journal of Medicine that found that two doses of the experimental mRNA-1273 vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2. The animal study results complemented the interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273 in healthy adults. The FDA authorized Moderna’s vaccine on December 18.
About Dr. Robert Seder
Dr. Seder received his B.A. in Natural Science at Johns Hopkins University in 1981 and his M.D. at Tufts University in 1986 and completed his residency in internal medicine at New York Hospital-Cornell Medical Center. Dr. Seder did his postdoctoral training at NIAID with Dr. William Paul studying how cytokines influence CD4+ T helper cell differentiation.
n 1994, Dr. Seder became chief of the Clinical Immunology Section in the Laboratory of Clinical Investigation, part of the NIAID Division of Intramural Research. Dr. Seder was then appointed to a tenured position in the Vaccine Research Center (VRC), Laboratory of Immunology in 2000. Since joining the VRC, Dr. Seder has focused his efforts on understanding the innate and adaptive mechanisms by which various vaccines approaches mediate protective antibody and T cell immunity in mouse, non-human primate and human models of HIV, malaria and tuberculosis infection. Dr. Seder is internationally recognized in the field of vaccine biology and cellular immunology. He currently serves as chief of the Cellular Immunology Section in the VRC.
Have a question for Dr. Seder you would like answered?
Submit it here!
Tuesday, May 18
7 to 8 pm EDT